CURE

Smoldering Multiple Myeloma: An Overview for Newly Diagnosed Patients

Smoldering multiple myeloma is an asymptomatic, precancerous condition with abnormal plasma cells and elevated monoclonal protein levels. Smoldering multiple myeloma is a complex, intermediary stage ...
CURE

Thoughts about Relapse of Multiple Myeloma

Nocturnal symptoms and musculoskeletal pain are filtered through relapse fear, driving repetitive interpretation of ...
The American Journal of Managed Care

Using MRD Data to Expedite Myeloma Treatment Delivery: Nicholas Richardson, DO, MPH

Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals. Under this framework, MRD negativity is ...
Informationsdienst Wissenschaft

Multiple myeloma: Established cancer drug reactivates immunotherapy

Home > Pressemitteilung: Multiple myeloma: Established cancer ...

C4 Therapeutics Maps Cemsidomide Phase II Launch, BCMA Combo Plans at Guggenheim Conference

C4 Therapeutics (NASDAQ:CCCC) executives outlined plans to advance their lead multiple myeloma program and expand the company ...
Seeking Alpha

Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

-- The D-Domain binder has a fast off-rate and contributes to anito-cel’s differentiated pharmacology profile in multiple myeloma -- -- A simulation model of CAR T use ahead of bispecific antibodies ...
Morningstar

Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings -- The D-Domain binder has a fast ...
Managed Healthcare Executive

FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals

FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.
Morningstar

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care Approval marks the twelfth ...

Established cancer drug can reactivate immunotherapy

Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune ...

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended ...
Le Lézard

Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease

Quest Diagnostics , a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced flow cytometry methods to assess measurable residual ...